Paper - WANFANG MED ONLINE

You Position: Home > Paper

Strategy of molecular drug design: dual-target drug design

( views:63, downloads:0 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 3

DOI:: 10.3321/j.issn:0513-4870.2009.03.001

Key Word:: 药物分子设计策略;双靶标药物;新药研究

Abstract：新药研究可分两种模式:以生理学和表型为基础的研究和以生物靶标为核心的药物研究,这两种模式相互补充和印证.当今以靶标为切入点的模式占主导地位,研发出不少新药.许多疾病如肿瘤、代谢性和中枢神经系统疾病的药物治疗非单一靶标可治愈,同时干预与疾病相关的双(多)靶标药物可提高药物的效力,因而成为创制新药的活跃领域.双靶标药物可以是两个受体的调节剂、两个酶的抑制剂或同时作用于酶和受体或作用于受体和通道或转运蛋白的双功能性分子等.从药物分子设计的视角,构建双靶标药物分子可将两个活性分子或其药效团用连接基连接在一起,构成连接型分子;两个活性分子的部分结构或药效团特征相同,可将共同部分融合或并合,形成融合型或并合型分子,可以控制分子的大小和相对分子质量,使得分子结构的药效空间与药代动力学空间有较大的重叠,提高成药的几率.

Reference

[1]M D, Meyer,A A, Hancock,K, Tietje,etc.Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT uptake inhibiting and alpha2-antagonistic activities.[J].1997,40.
[2]Veber DF,Johnson SR,Cheng HY,etc.Molecular properties that influence the oral bioavailability of drug candidates.[J].2002,45(12).
[3]Macor JE,Baska RA,Beyer SM,etc.Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.[J].2002,45(18).
[4]P C, Unangst,D T, Connor,W A, Cetenko,etc.Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity.[J].1994,37(2).
[5]Hullinger T.The effect of a novel, dual function histamine H(1) receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation.[J].2005,506(3).
[6]Richard Morphy,Zoran Rankovic.Designed Multiple Ligands.An Emerging Drug Discovery Paradigm[J].2005,48(21).
[7]R E, Mewshaw,J, Kavanagh,G, Stack,etc.New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans.[J].1997,40.
[8]Contreras JM,Wermuth CG,Rival YM,etc.Design, synthesis, and structure-activity relationships of a series of 3-(2-(1-benzylpiperidin-4-yl)ethylamino)pyridazine derivatives as acetylcholinesterase inhibitors.[J].2001,44(17).
[9]Murugesan N,Yang YF,Monshizadegan H,etc.Dual angiotensin II and endothelin a receptor antagonists: Synthesis of 2 '-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics[J].2005,48(1).
[10]Xie Z,Kulkarni A,Bhushan RG,etc.A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes.[J].2005,48(6).
[11]E S, Lazer,H C, Wong,G J, Possanza,etc.Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols.[J].1989,32(1).
[12]Ahmad LJ,Takeuchi K,Honigschmidt NA,etc.Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4.[J].2004,14(10).
[13]Jean Luc Malleron,Claude Gueremy,Serge Mignani,etc.New indole derivatives as potent and selective serotonin uptake inhibitors[J].1993,36(9).
[14]T I, Nicas,D L, Mullen,J E, Flokowitsch,etc.Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.[J].1996,40.
[15]Rigas B,Kashfi K.Nitric-oxide-donating NSAIDs as agents for cancer prevention.[J].2004,10(7).
[16]J A, Robl,C Q, Sun,J, Stevenson,etc.Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.[J].1997,40.
[17]Meagher KristinL,Mewshaw RichardE,Zhou Dahui,etc.Studies toward the discovery of the next generation of antidepressants. Part 2: incorporating a 5-HT(1A) antagonist component into a class of serotonin reuptake inhibitors.[J].2002,12(3).
[18]Paul C. Unangst,David T. Connor,Wiaczeslaw A. Cetenko,etc.Oxazole, thiazole, and imidazole derivatives of 2,6-di-tert-butylphenol as dual 5-lipoxygenase and cyclooxygenase inhibitors[J].1993,3(8).
[19]Perez-Silanes S,Lasheras B,Bosch A,etc.New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.[J].2001,44(3).
[20]Morphy R,Kay C,Rankovic Z.From magic bullets to designed multiple ligands.[J].2004,9(15).
[21]Humphrey PP,Gao Q,Karr DE,etc.Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.[J].2005,49(3).
[22]Williams C,Qiu Q,Brahimi F,etc.Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure-activity relationship[J].2007,50(11).
[23]P.Minuz,C.Lechi,S.Bonapace,etc.Effects of a new class of no-releasing NSAIDs on platelets and isolated arteries[J].1996,4(1).
[24]Cena C,Gasco A,Tosco P,etc.NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.[J].2007,50(7).
[25]Borisy AA,Elliott PJ,Hurst NW,etc.Systematic discovery of multicomponent therapeutics.[J].2003,100(13).
[26]Soyka R,Guth BD,Weisenberger HM,etc.Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.[J].1999,42(7).
[27]Michael R.Leadbetter,Paul R.Fatheree,Kevin M.Krause,etc.Hydrophobic Vancomycin Derivatives with Improved ADME Properties:Discovery of Telavancin (TD-6424)[J].2004,57(5).
[28]Edward S. Lazer,Hin Chor Wong,Craig D. Wegner,etc.Effect of structure on potency and selectivity in 2,6-disubstituted-4-(2-arylethenyl)phenol lipoxygenase inhibitors[J].1990,33(7).
[29]J F, Kerwin,J R, Lancaster,P L, Feldman.Nitric oxide: a new paradigm for second messengers.[J].1995,38(22).
[30]Keith CT,Lehar J,Zimmermann GR.Multi-target therapeutics: when the whole is greater than the sum of the parts.[J].2007,12(1).
[31]Pontikis R,Dolle V,Guillaumel J,etc.Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.[J].2000,43(10).
[32]Morphy R,Rankovic Z.Fragments, network biology and designing multiple ligands.[J].2007,12(3/4).
[33]Al-Lazikani B,Hopkins AL,Overington JP.How many drug targets are there?[J].2006,5(12).
[34]Henrik Daub,Katja Specht,Axel Ullrich.Strategies to Overcome Resistance to Targeted Protein Kinase Inhibitors[J].2004,3(12).
[35]Williams C,Rachid Z,Larroque AL,etc.Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties.[J].2007,17(15).